Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

about

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Item

http://www.wikidata.org/entity/Q58776910

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Efficacy of the combination of ...... ractory acute myeloid leukemia

@en

Efficacy of the combination of ...... ractory acute myeloid leukemia

@nl

type

Item

label

Efficacy of the combination of ...... ractory acute myeloid leukemia

@en

Efficacy of the combination of ...... ractory acute myeloid leukemia

@nl

prefLabel

Efficacy of the combination of ...... ractory acute myeloid leukemia

@en

Efficacy of the combination of ...... ractory acute myeloid leukemia

@nl

P1476

Efficacy of the combination of ...... ractory acute myeloid leukemia

@en

P2093

Ahmed Aribi

http://www.w3.org/2001/XMLSchema#string

Amandeep Salhotra

http://www.w3.org/2001/XMLSchema#string

Anthony S Stein

http://www.w3.org/2001/XMLSchema#string

David Snyder

http://www.w3.org/2001/XMLSchema#string

Dongyun Yang

http://www.w3.org/2001/XMLSchema#string

Haris Ali

http://www.w3.org/2001/XMLSchema#string

Ibrahim Aldoss

http://www.w3.org/2001/XMLSchema#string

Karamjeet Sandhu

http://www.w3.org/2001/XMLSchema#string

Margaret O'Donnell

http://www.w3.org/2001/XMLSchema#string

Monzr M Al Malki

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Azacitidine for the treatment of relapsed and refractory AML in older patients.

P304

e404-e407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2018.188094

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Matthew Mei

Guido Marcucci

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29545346

http://www.w3.org/2001/XMLSchema#string

P921

hematology

leukemia

P932

6119155

http://www.w3.org/2001/XMLSchema#string